ClinicalTrials.gg
Not yet recruitingNCT05572034CardioSyncUpdated Aug 18, 2023

Cardiac Autonomic Denervation for Cardio-inhibitory Syncope

An interventional study of Electrophysiological study and Electrophysiological study and Right side Ganglionated Plexi ablation in Bradycardia; Syncope and Syncope, Vasovagal, sponsored by University of Sao Paulo General Hospital. Not yet recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Background: Autonomic system modification is an established therapeutic approach that has been increasingly used for the treatment of vagal-related symptomatic bradycardia, such as cardio-inhibitory vasovagal syncope1-12.

Although convincing results had been reported from small populations, a large randomized study providing robust evidence on the efficacy of this approach has not yet been performed.

Hypothesis: Cardiac autonomic system modification is effective for the treatment of vagal-related symptomatic bradycardia, and is associated better clinical results as compared to placebo.

02

Conditions studied

  • Bradycardia; Syncope
  • Syncope, Vasovagal

Keywords

  • Cardiac denervation
  • Cardio-inhibitory syncope
03

In context

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

This study's planned enrollment of 45 is below the median of 100 across 187 interventional studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

University of Sao Paulo General Hospital is the lead sponsor of 611 studies on the registry; 98 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 70 years old.
  • Cardio-inhibitory response (VASIS 2A or 2B) during tilt test, or after carotid sinus massage.
  • Patients with bradycardia mediated by vagal hypertonia documented on 24-hour Holter monitoring and a clear relationship with symptoms.

Exclusion criteria

Exclusion Criteria:

  • Ages under 18 and over 70
  • Presence of structural heart disease documented by echocardiography.
  • Hypothyroidism and hyperthyroidism, drug effects, obstructive sleep apnea and other causes of secondary bradycardia.
  • Anatomical disease of the conduction system.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (estimated)

Study arms

  • Sham comparator
    Group A

    A diagnostic electrophysiological study will be performed in patients of group A

    Procedure: Electrophysiological study

  • Active comparator
    Group B

    A electrophysiological study with cardiac denervation, with right Ganglionated Plexi ablation exclusively will be performed in patients of group B

    Procedure: Electrophysiological study and Right side Ganglionated Plexi ablation

  • Active comparator
    Group C

    A electrophysiological study with cardiac denervation, with right and left Ganglionated Plexi ablation will be performed in patients of group C.

    Procedure: Electrophysiological study and bi-atrial Ganglionated Plexi ablation

Interventions

  • ProcedureElectrophysiological study

    Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.

  • ProcedureElectrophysiological study and Right side Ganglionated Plexi ablation

    Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome. GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works (anatomic mapping): In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and, the septal aspect of the superior vena cava junction (opposite to the LA GP tags). A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow.

  • ProcedureElectrophysiological study and bi-atrial Ganglionated Plexi ablation

    Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome. GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works(anatomic mapping): In the LA: the inferior right GP (septal aspect of the right pulmonary veins \[PV\]) antra, and LA posterior wall. In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and the septal aspect of the superior vena cava junction (opposite to the LA GP tags). A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow.

06

What researchers measure

Primary outcomes

  1. recurrence of syncope

    To compare the recurrence of syncope or pre-syncope and a negative tilt test with the different techniques of electrophysiological procedures currently used.

    Time frame: 24 months

Secondary outcomes

  1. electrocardiographic and electrophysiological parameters

    Compare the following electrocardiographic and electrophysiological parameters of vagal attenuation: * Heart rate (bpm - beats per minute); * Internal AH (represents AV internodal conduction time, with normal values between 50-120 ms); * Wenckebach cycle; * Presence of Holter pauses 30 days after the intervention.

    Time frame: 24 months

07

Study locations

2 sites
  • University of Sao Paulo General Hospital
    Sao Paulo, SP 01246-000, Brazil
    • Mauricio I Scanavacca, MD, PhD · Contactmauricio.scanavacca@gmail.com · +551126615341
    • Esteban W Rivarola, MD, PhD · Contacteteban@hotmail.com · +551126615341
    • Mauricio I Scanavacca, MD, PhD · Principal investigator
    • Esteban W Rivarola, MD, PhD · Sub investigator
    • Gabrielle D Pessente, BsC, MS · Sub investigator
  • Arrhythmia and electrophysiology of the Heart Institute - University of São Paulo
    São Paulo, 05403-900, Brazil
    • Gabrielle D Pessente, BSc, MS · Contactgabrielle.pessente@hc.fm.usp.br · +55 11 26615712
    • Esteban W Rivarola, MD, PhD · Sub investigator
    • Mauricio I Scanavacca, MD, PhD · Principal investigator
08

References and documents

Publications

  • Hardy C, Rivarola E, Scanavacca M. Role of Ganglionated Plexus Ablation in Atrial Fibrillation on the Basis of Supporting Evidence. J Atr Fibrillation. 2020 Jun 30;13(1):2405. doi: 10.4022/jafib.2405. eCollection 2020 Jun-Jul. PubMed 33024505 ↗
  • Sarabanda AV, Melo SL, Rivarola E, Hachul D, Scanavacca M. Anatomically guided atrial ganglionated plexus ablation evaluated by extracardiac vagal stimulation for vagally mediated atrioventricular block. HeartRhythm Case Rep. 2021 Feb 10;7(5):301-305. doi: 10.1016/j.hrcr.2021.02.002. eCollection 2021 May. No abstract available. PubMed 34026520 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Dec 2023, 3 months later.

Of 47 non-industry interventional studies with no phase under Bradycardia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 3 months is below that.

Counting every sponsor, half of 83 studies reached it within 21 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
Oct 7, 2022
StartEst.
Sep 1, 2023
Primary completionEst.
Dec 30, 2023
CompletionEst.
Mar 30, 2024
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05572034
Collaborators
Abbott
Responsible party
Mauricio Ibrahim Scanavacca (Director of arrhythmia and electrophysiology Unit, University of Sao Paulo General Hospital) — Principal investigator
First posted
Oct 7, 2022
Start date
Sep 1, 2023 (estimated)
Primary completion
Dec 30, 2023 (estimated)
Completion
Mar 30, 2024 (estimated)
Last update
Aug 18, 2023

Study contacts

Mauricio I scanavacca, MD, PhD
Contact
mauricio.scanavacca@incor.usp.br
+ 55 11 26615341
Esteban W Rivarola, MD, PhD
Contact
eteban@hotmail.com
+55 11 26615341
Mauricio I Scanavacca, MD, PhD
principal investigator · University of Sao Paulo - General Hospítal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion